A Cancer Driven by Ultra-Rare Mutation Gets Its First FDA-Approved Therapy

Frank Vinluan / medcitynews - Partner Therapeutics’ Bizengri is now FDA approved for treating advanced cases of cholangiocarcinoma driven by NRG1 gene fusions. Partner acquired U.S. rights to this bispecific antibody from Merus in 2024. The post A Cancer Driven by Ultra-Rare Mutation …

AI Summary: The FDA approved zenocutuzumab‑zbco for NRG1‑fusion–positive cholangiocarcinoma, delivering the first cleared therapy for cancers driven by this ultra‑rare genomic alteration. Trial data showed meaningful responses in heavily pretreated patients, prompting regulators to greenlight a precision option that offers targeted benefit where none existed — a small‑population win for genomic oncology.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 15 days

Datroway secures regulatory approvals in breast cancer across US and EU / 8 days

FDA grants early access to experimental pancreatic cancer drug / 29 days

FDA approves relacorilant plus nab‑paclitaxel for resistant ovarian cancers / 7 wks

FDA flags misleading cancer drug claims tied to biotech billionaire / 2 months

Rogaratinib shows activity in SDH‑deficient GIST phase 2 trial / 43 hrs

FDA clears pivekimab sunirine (Decnupaz) as first BPDCN ADC / 46 hrs